Miscellaneous antineoplastics
https://themeditary.com/dosage-information/welireg-dosage-1171.html

Welireg Dosage

Drug Detail:Welireg (Belzutifan)

Generic Name: BELZUTIFAN 40mg

Dosage Form: tablet, film coated

Drug Class: Miscellaneous antineoplastics

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Recommended Dosage

The recommended dosage of WELIREG is 120 mg administered orally once daily until disease progression or unacceptable toxicity. WELIREG should be taken at the same time each day and may be taken with or without food.

Advise patients to swallow tablets whole. Do not chew, crush, or split WELIREG prior to swallowing.

If a dose of WELIREG is missed, it can be taken as soon as possible on the same day. Resume the regular daily dose schedule for WELIREG the next day. Do not take extra tablets to make up for the missed dose.

If vomiting occurs any time after taking WELIREG, do not retake the dose. Take the next dose on the next day.

Dosage Modifications for Adverse Reactions

Dosage modifications for WELIREG for adverse reactions are summarized in Table 1.

The recommended dose reductions are:

  • First dose reduction: WELIREG 80 mg orally once daily
  • Second dose reduction: WELIREG 40 mg orally once daily
  • Third dose reduction: Permanently discontinue
Table 1: Recommended Dosage Modifications for Adverse Reactions
Adverse Reaction Severity Dosage Modification
Anemia
[see Warnings and Precautions (5.1)]		 Hemoglobin <9 g/dL or transfusion indicated
  • Withhold until hemoglobin ≥9g/dL.
  • Resume at reduced dose or discontinue depending on the severity of anemia.
Life-threatening or urgent intervention indicated
  • Withhold until hemoglobin ≥9g/dL.
  • Resume at a reduced dose or permanently discontinue.
Hypoxia
[see Warnings and Precautions (5.2)]		 Decreased oxygen saturation with exercise (e.g., pulse oximeter <88%)
  • Consider withholding until resolved.
  • Resume at the same dose or at a reduced dose depending on the severity of hypoxia.
Decreased oxygen saturation at rest (e.g., pulse oximeter <88% or PaO2 ≤55 mm Hg) or urgent intervention indicated
  • Withhold until resolved.
  • Resume at reduced dose or discontinue depending on the severity of hypoxia.
Life-threatening or recurrent symptomatic hypoxia
  • Permanently discontinue.
Other Adverse Reactions
[see Adverse Reactions (6)]		 Grade 3
  • Withhold dosing until resolved to ≤ Grade 2.
  • Consider resuming at a reduced dose (reduce by 40 mg).
  • Permanently discontinue upon recurrence of Grade 3.
Grade 4
  • Permanently discontinue.
Share this Article
Latest News
Related Drugs